[1] 孙振,葛鹏磊,高志强,等.进展期胆囊癌患者术后应用替吉奥联合吉西他滨的临床疗效[J].中华肝胆外科杂志,2018,24(1):29-33. [2] Li J,Yang ZL,Ren X,et al.ACE2 and FZD1 are prognosis markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of gallbladder[J].J Mol Histol,2014,45(1):47-57. [3] 徐建庆,陈晨,宋虎伟,等.胆囊癌发病相关危险因素分析[J].中国普通外科杂志,2015,24(2):190-194. [4] 耿智敏,王林,陈晨,等.438例胆囊癌外科治疗及预后因素分析[J].中华消化外科杂志,2016,15(4):346-352. [5] 孟强劳,王林,耿智敏,等.进展期胆囊癌新辅助化疗研究进展[J].中华肝胆外科杂志,2017,23(11):789-792. [6] Cariati A.Gallbladder cancers: Associated conditions, histological types, prognosis, and prevention[J].Eur J Gastroenterol Hepatol,2014,26(5):562-569. [7] 杨金珠.晚期胆囊癌应用吉西他滨联合替吉奥方案化疗的临床疗效[J].肝胆外科杂志,2016,24(3):196-197. [8] Onuki K,Sugiyama H,Ishige K,et al.Expression of N-acetylglucosaminyltransferase V in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder[J].J Gastroenterol,2014,49(4):702-714.
2019, Vol. 36 
